Melatonin, vitamins and minerals supplements for the treatment of Covid-19 and Covid-like illness: A prospective, randomized, double-blind multicenter study

被引:5
|
作者
Mahjoub, Lobna [1 ]
Youssef, Rym [1 ]
Yaakoubi, Hajer [1 ]
Ben Salah, Houda [1 ]
Jaballah, Rahma [1 ]
Mejri, Moez [1 ]
Sekma, Adel [2 ]
Trabelsi, Imen [2 ]
Nouira, Semir [2 ]
Khrouf, Mariem [3 ]
Ben Soltane, Houda [3 ]
Mezgar, Zied [3 ]
Boukadida, Lotfi [1 ]
Zorgati, Asma [1 ]
Boukef, Riadh [1 ]
机构
[1] Sahloul Univ Hosp, Emergency Dept, Sousse 4011, Tunisia
[2] Monastir Univ, Res Lab LR12SP18, Monastir 5019, Tunisia
[3] Farhat Hached Univ Hosp, Emergency Dept, Sousse 4031, Tunisia
关键词
Melatonin; Zinc; Vitamin C; Vitamin D; Covid-19; Emergency department; INFECTION; ZINC;
D O I
10.1016/j.explore.2023.06.009
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Melatonin, zinc, and multivitamins are among most recommended supplements in the fight against coronavirus disease 2019 (COVID-19). We aimed to examine the efficacy and safety of this association in the treatment of COVID-19 and COVID-like illnesses. Methods: We conducted a multicenter prospective, randomized, double-blind, controlled trial. Patients with no medical history consulting the emergency department for covid and covid-like illness and who were not hospitalized were included. Patients were assigned in a 1:1 ratio to the treatment or the placebo group. The primary outcome was studying the effectiveness of zinc multivitamin supplement and melatonin in the treatment of COVID and -like illnesses symptoms' according to the time from randomization to clinical improvement. The prespecified secondary outcomes were date of disappearance of symptoms present on admission, appearance of an adverse effect due to the administration of the treatment, number of patients developing complications, requiring hospitalization, requiring respiratory support. Results: One hundred sixty four patients were eligible for the study and were randomized to either the treatment group or the placebo group. Overall, 128 of the 164 patients had a PCR for SARS-CoV-2, yielding a positive PCR result in 49.1% of them. Regarding the disappearance of all initial presenting symptoms: on the 5(th) day of the follow-up, there was a significant difference between the two groups with a p value 0.04;On the 10th day, there was a significant difference too with p value of 0.038. There were no significant differences between the two groups in recovery during the 15th day of follow-up p>0.5. Finally, 100% of patients fully recovered in the treatment group vs 98.8% in the placebo group. No severe adverse events were reported throughout the trial. Conclusions: Our results showed that daily doses of Melatonin, zinc and vitamins did significantly reduce the duration of symptoms accelerating its disappearance among patients consulting with COVID-19 or COVID-19 like illness.
引用
收藏
页码:95 / 100
页数:6
相关论文
共 50 条
  • [21] Soy isoflavones and melatonin for the relief of climacteric symptoms: a multicenter, double-blind, randomized study
    Secreto, G
    Chiechi, LM
    Amadori, A
    Miceli, R
    Venturelli, E
    Valerio, T
    Marubini, E
    MATURITAS, 2004, 47 (01) : 11 - 20
  • [22] Efficacy and Safety of Inosine Pranobex in COVID-19 Patients: A Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trial
    Jayanthi, C. R.
    Swain, Ashok K.
    Ganga, Ranganath T.
    Halnor, Dnyaneshwar
    Avhad, Ajit
    Khan, Mohd Saif
    Ghosh, Ayan
    Choudhary, Sumer Sanjiv
    Yannawar, Anand Namdevrao
    Despande, Shubhangi
    Patel, Manish
    Anne, Krishna Prasad
    Bangar, Yogesh
    ADVANCED THERAPEUTICS, 2022, 5 (12)
  • [23] Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial
    Pourdowlat, Guitti
    Saghafi, Fatemeh
    Mozafari, Abolfazl
    Sahebnasagh, Adeleh
    Abedini, Atefeh
    Nabi Meybodi, Mohsen
    Salehi Nezamabadi, Ali
    Mousavinasab, Seyed Ruhollah
    Kiani, Arda
    Raji, Hanieh
    Soltani, Nadia
    Gholmzadeh Baeis, Mehdi
    Eidani, Esmaeil
    Sadeghi Yakhdani, Abdolrahim
    Movaseghi, Fatemeh
    Habtemariam, Solomon
    Akhoundi Meybodi, Zohreh
    Gholinataj Jelodar, Mohsen
    PHYTOTHERAPY RESEARCH, 2022, 36 (02) : 891 - 898
  • [24] RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial
    Holubovska, Olga
    Babich, Pavlo
    Mironenko, Alla
    Milde, Jens
    Lebed, Yuriy
    Stammer, Holger
    Mueller, Lutz
    te Velthuis, Aartjan J. W.
    Margitich, Victor
    Goy, Andrew
    ADVANCES IN RESPIRATORY MEDICINE, 2024, 92 (03) : 202 - 217
  • [25] Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19: A Phase 2 Randomized Controlled Double-Blind Study
    Muscedere, John
    Maslove, David M.
    Barden, Christopher J.
    Weaver, Donald F.
    Boyd, J. Gordon
    Sibley, Stephanie
    Boyd, Tracy
    Rewa, Oleksa
    Albert, Martin
    Roussos, Marios
    Norman, Patrick A.
    Day, Andrew G.
    CRITICAL CARE EXPLORATIONS, 2024, 6 (02) : E1045
  • [26] Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial
    Ventura-Enriquez, Yanet
    Cabello-Gutierrez, Carlos
    Augusto Perez-Calatayud, Angel
    Cortina-De la Rosa, Evelyn
    Javier Fareli-Gonzalez, Christian
    Castillo-Juarez, Paola
    Pena-Perez Carlos, Alberto
    Omar Zavaleta-Martinez, Eli
    Diaz-Padilla, Elizabeth
    Murrieta, Sandra
    Deyanira Alvarez-Jimenez, Violeta
    Diaz Ponce-Medrano, Juan Alberto
    Casillas-Suarez, Catalina
    Angelica Ocampo-Ocampo, Maria
    Vargas-De-Leon, Cruz
    Fernandez-Sanchez, Veronica
    LIFE-BASEL, 2022, 12 (11):
  • [27] A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
    Taku Kinoshita
    Masahiro Shinoda
    Yasuhiro Nishizaki
    Katsuya Shiraki
    Yuji Hirai
    Yoshiko Kichikawa
    Kenji Tsushima
    Masaharu Shinkai
    Naoyuki Komura
    Kazuo Yoshida
    Yasutoshi Kido
    Hiroshi Kakeya
    Naoto Uemura
    Junichi Kadota
    BMC Medicine, 20
  • [28] A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
    Kinoshita, Taku
    Shinoda, Masahiro
    Nishizaki, Yasuhiro
    Shiraki, Katsuya
    Hirai, Yuji
    Kichikawa, Yoshiko
    Tsushima, Kenji
    Sinkai, Masaharu
    Komura, Naoyuki
    Yoshida, Kazuo
    Kido, Yasutoshi
    Kakeya, Hiroshi
    Uemura, Naoto
    Kadota, Junichi
    BMC MEDICINE, 2022, 20 (01)
  • [29] Efficacy and safety of add-on Viola odorata L. in the treatment of COVID-19: A randomized double-blind controlled trial
    Mehraban, Mohammad Sadegh Adel
    Shirzad, Meysam
    Kashani, Leila Mohammad Taghizadeh
    Ahmadian-Attari, Mohammad Mahdi
    Safari, Ali Akbar
    Ansari, Narges
    Hatami, Hossein
    Kamalinejad, Mohammad
    JOURNAL OF ETHNOPHARMACOLOGY, 2023, 304
  • [30] Letter to the editor: Ef fi cacy of probiotic treatment as postexposure prophylaxis for COVID-19: A double-blind, PlaceboControlled randomized trial
    Ji, Yuan
    Chen, Jinhan
    Chi, Yuying
    Ying, Yuou
    Chen, Mingxian
    CLINICAL NUTRITION, 2024, 43 (06) : 1501 - 1502